---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299931380.md"
description: "Wave Life Sciences shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral rating. The company also announced the initiation of its Phase 2a clinical trial evaluating WVE-007 in combination with tirzepatide in adults living with obesity."
datetime: "2026-09-23T17:32:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299931380.md)
  - [en](https://longbridge.com/en/news/299931380.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299931380.md)
generator: "portal-rs"
---

# 

Wave Life Sciences shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral rating. The company also announced the initiation of its Phase 2a clinical trial evaluating WVE-007 in combination with tirzepatide in adults living with obesity.

### Related Stocks

- [WVE.US](https://longbridge.com/en/quote/WVE.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [WVE: Pipeline progress and $431 million in cash support an expected runway into Q3 2028](https://longbridge.com/en/news/303225722.md)
- [Wave Life Sciences Q3 revenue jumps, beats estimates](https://longbridge.com/en/news/303223998.md)
- [WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path](https://longbridge.com/en/news/302638760.md)
- [WAVE Life Sciences (WVE) Set to Release Earnings on Tuesday](https://longbridge.com/en/news/302687866.md)
- [Wave Life Sciences starts Phase 2a trial of WVE-007 with tirzepatide for obesity](https://longbridge.com/en/news/299888250.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**